Episode Details

President Trumps deal with Eli Lilly and Novo Nordisk brings affordable weight loss drugs to market. Eli Lillys Foundayo, a once-daily GLP-1 med, starts shipping Monday, with insured folks possibly paying just $25 a month. Novo Nordisks Wegovy, already popular, also uses GLP-1 technology. These drugs, originally for diabetes, now target weight loss, curbing appetite and boosting fullness signals. Medicare and private plans may cover them, potentially reshaping obesity care.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/94840a0059758f9d